DOCSLIB.ORG

G Protein-Coupled Receptor Drugs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
G Protein-Coupled Receptor Drugs Baran Group Meeting Lisa M. Barton G Protein-Coupled Receptor Drugs 5/4/19 Introduction GPCR Classes • G Protein-Coupled Receptors (GPCRs) are very important for human biology A-F System: Based on amino - Largest family of membrane-bound receptors acid sequences and functional - Over 350 non-olfactory GPCRs in humans, ~1/3 similarities, covers GPCRs in of which have been drugged invertebrates and vertebrates - Expressed on all cells in the body - Regulate numerous diverse physiological Class A or Rhodopsin processes including intercellular Class B or Secretin communication and signal transmission Class C or Glutamate - Over 30% of approved drugs target GPCRs Class D or Fungal Mating - Between 2011-2015 represented ~27% of the Pheromone (not in vertebrates) global market share of therapeutic drugs and Class E or cAMP receptors generated ~$890 billion (not in vertebrates) Class F or Frizzled/smoothened receptors GRAFS System: Based on phylogenetic tree, covers only human GPCRs G or Glutamate R or Rhodopsin A or Adhesion F or Frizzled/Taste2 S or Secretin From Trends in Pharm. Sci. 2012, 33, 17 Mol. Pharma. 2003, 63, 1256 Definitions • Agonist - mimic function of natural ligands by binding to receptor and causing the normal response • Partial Agonist - any agonist that produce the maximum response capable in a system even at saturating From Nat. Rev. Drug Discov. 2017, 16, 829 concentrations • Most GPCR-targeting drugs were not initially devoped to target a specific protein but • Antagonist - bind to receptor and prevent normal response rather by functional activity by inhibiting natural ligand from binding; keeps response of • Increase in GPCR crystal structures (>40), advances in receptor at basal levels. Could be either competitive biophysical techniques, and computational methods has (reversible) or non-competitive (irreversible). led to increases in structure-based drug discovery • Inverse Agonist - different than simple antagonist as will • 1967, 1970 1971, 1988, 1994, 2000, 2004 and 2012 switch a receptor into an "off" state; this cause a response Novel Prizes were awarded for GPCR related research that lowers response bellow basal levels • Allosteric Inhibitor - acts by binding to a site that is Group Meeting Includes topographically disctint from, but conformationally linked to, • Introduction to GPCRs, their structure, and the active site basic functions • Potency - the dose range over which a response is • Adrenergic and Anglotensin Receptors produced; from a dose-reponse cure the potency is the dose • Histamine Receptors of the drug that produces 50% of the maximum response • Dopamine and 5-HT (Serotonin) Receptors (ED50) • Muscarinic Receptors Group Meeting Doesn't Include • Efficacy - the size/strength of a response produced by an • Adenosine Receptors • An exhaustive discussion of any of these agonist in a particular tissue • Opioid Receptors topics • Chemokine Receptors • Many of the lesser-targeted GPCRs With GPCR Drugs it is not always clear exactly what kind of interaction they have with a • Gonadotropin-releasing Hormone Receptors • Orphan GPCRs particular receptor and there are many cases where a drug has been re-catagorized as a better • List of Validated GPCR Drug Targets • In depth biology on individual GPCRs understanding of the mechanism of action is gained from biological studies Baran Group Meeting Lisa M. Barton G Protein-Coupled Receptor Drugs 5/4/19 Adrenergic Receptors (ARs) Structure of GPCRs Agonists: OH • Also classified as α-1 Adrenergic Recep All share same transmembrane domain • Epinephrine primarily released by the adrenal gland whereas HO NHR with common structure: Norepinephrin released by sympathetic nerve terminals in peripheral • 7 transmembrane domains that are nervous system and brain HO hydrophobic α-helices • Play key role in cardiac function • 3 extracellular loops • 2 classes: β-ARs (~90% total ARs in heart) and α-ARs (~10%) R = Me: Epinephrine • 3 intracellular loops (adrenaline) • Each classes can be further subdived into α1, α2, β1,β2 and β3 • N-terminus (responsible for ligand binding) • Targeting this GPCR class lead to development of Beta Blockers R = H: Norepinephrin • C-terminus • Drugs targeting these receptors also have indications in treatment O of asthma and COPD i OH GPCR Signaling Pathway OH PrHN Select Examples: O NHiPr N t O O NH Bu O Me N nPr N S N OH H O Acebutolol (Sectral®) Propranolol (Inderal®) Timolol (Betimol®) Sanofi AZ Akorn Pharma Angiotensin Receptors (ATs) • Angiotensin is a hormone made by the liver that is further converted to Angiotensin I and II by therenin-angiotensin enzymatic cascade • Angiotensin II plays an important role in cardiovascular system • 3 classes: AT1, AT2, and Mas which differ in their affinity for various angiotensin peptide fragments • Targeting this GPCR class lead to development of Angiotensin II Receptor Blockers (ARBs); unlike ACE inhibitors (which only can prevent the formation of angiotensin by the renin-angiotensin enzymatic cascade) these can block all angiotensin as they prevent their binding to receptors HN NH2 NH OH Agonists: N From Exp. Mol. Med. 2016, 48, e207 • GPCRs in constant motion HO Angiotensin II O O O N O • Agonist binding stabalizes GPCR into "On" conformation H H H HO N N • Agonists can range from ions and small molecules to peptides and large proteins depending N N N O on the type of receptor HN O NH H O H O H N • "On" conformation further stabalized by binding of G-protein (made up of α, β and γ subunits) 2 Me Me Me O • Note little is known about how GPCRs associate with specific G-proteins Select Examples: HO C Me • Once G protein encounters ligand-bound GPCR, GDP is exchanged with GTP; triggers 2 N N N NH release of Gβγ dimer. Cl N •MsOH N NH nBu • Both free Gα and Gβγ can interact with effector molecules in cells, trigger downstream signaling N N CO2H N O N nBu • Pathway stops when Gα hydrolyzes GTP to GDP and reassociates with Gβγ. N N • There are multiple pathways through which GPCRs can become desensitized, including S nBu receptor phosphorylation events, arresting-mediated internalization into endosomes, receptor OH recycling and lysosomal degradition Losartan (Cozaar®) Eprosartan Mesylate (Teveten®) Irbesartan (Avapro®) • Many GPCRs can trigger multiple different signalling pathways and specific ligands can Merck GSK Sanofi/BMS produce different relative efficacies to different pathways (sometimes even opposite, ie acting For more details on drugs that target both these receptors see Cardiovascular (CV) Drugs as both an agonist for 1 and an antagonist for another) Group Meeting (Merchant 2018) Baran Group Meeting Lisa M. Barton G Protein-Coupled Receptor Drugs 5/4/19 nd OMe Histamine Receptors 2 generation: F Astemizole Me • Histamine is naturally produced from L-histidine by histidine decarboxylase in (Hismanal®) Cl N a number of different cell types and is involved in the regulation of a number of Agonist: O H N N different body functions (ie cell proliferation, hematopoiesis, wound healing, N N sleep/wake cycle, cognition memory, etc) N NH2 N N • 4 different classes: H1-H4 HN N Azelastine Ph OH • Indications of drugs that act as histamine antagonists range from treatment Histamine (Astelin®) N of allergic conditions (H1), peptic ulcers (H2), obesity and CNS disorders (H3), R= Me: Terfenadine (Seldane®) OH Ph R and asthma and inflammation (H ) 4 For a review on Histamine Receptors see N R= CO2Et: Br. J. Pharmacol. 2006, 147, S127 Loratadine In response to external stimuli Cl Me cell release of inflammatory Me (Claritin®) mediators such as Histamine Ph Acrivastine R= CO2H R R= H: Fexofenadine Me Histamine (Benadryl Allergy Desloratadine Cytokine and chemokine production ® N Adhesion molecule production (Allegra ) Vasodilation ® (Clarinex®) Allergy and inflammation Bronchoconstriction Relief ) Vasodilation H1R Platelet aggregation N Bronchoconstriction Mucus hyper-secretion HO C O Cl Platelet aggregation HO2C N 2 N Gaq/11 racemic: chiral: Ca2+ Ca2+ Ca2+ Cetirizine (Zyrtec®) Levocetirizine (Xyzal®) H4R Gai/o Gas H2R Ca2+ OPRD 2012, 16, 1279 Gai/o Ph Ca2+ release from ER Degrannulation Gastric acid secretion OH Increase in heart rate Chemotaxis H3R Ph O CONH2 Immunomodulation and cardiac output N + Cl Sleep-wake cycle, cognition, HN (34% overall yield) Homeostatic regulation of energy levels, Cl + A Neurotransmission N Cl O + Cl O CO2Me H1 Receptors Cl A + Cl NMe • H -recptor is widely expressed (nerves, 2 N 1 H Cetirizine (10% overall yield) respiratory epithelium, endothelial cells, hepatic cells, vascular smooth muscle cells, dendritic O cells, lymphocytes) O CN O A + Cl • Involved in allergy and inflammation Ph Cl X Crystal structure of H1 receptor complexed with Ph ("good yeild") • Antihistamines all act as inverse agonists and doxepin; Nature 2011, 475, 65 + NR lock into inactive state Cl O • 1st gen histadines: sedating HN N + Cl X = ONa (56%) • 2nd gen: relatively nonsedating Cl N X X = OH (67%) • 6 Chemical Classes of Antihistamines: – Ethanolamines – Phenothiazines – Piperazines HO Cl – Ethylenediamines – Alkylamines – Piperidines Ways to make chiral (Levocetirizine): Select examples of H Antihistamines 1 O st Clemastine S 1 generation: Br N tBu 1. PhMgBr, Tol (Meclastin®) NH2 Cl -20 to 0 ºC Me Ph 65%, >99% ee Ph N N NMe2 O 2. HCl, MeOH Ph O racemic: Brompheniramine Cl 95% Cl Diphenhydramine Me Levocetirizine NMe2 (Dimetapp®) OH (Benadryl®) NMe2 O chiral: CBS NMe2 Me N Dexbrompheniramine Reduction Chloropyramine N (Drixoral®) 99% Cl N Promethazine Cl 98% ee Cl ® Cr(CO) Cr(CO)3 Tetrahedron Lett. 1996, 37, 4837 S (Phenergan ) 3 Tetrahedron Lett. 2002, 43, 923 Baran Group Meeting Lisa M. Barton G Protein-Coupled Receptor Drugs 5/4/19 Med Chem and Process Routes: NMe CH2O 2 SH NMe2 Cl Me NH H N Me Cl HO 2 2 S O O O Cl cat H+ conc. HCl H2N POCl3 (from furfuryl) t OH 50-82% NH Bu NHtBu N n-BuLi MeS SMe MeS NHMe N 94% OH 92% 1.
Load more

Recommended publications
  • The G Protein-Coupled Receptor Subset of the Dog Genome Is More Similar
    BMC Genomics BioMed Central Research article Open Access The G protein-coupled receptor subset of the dog genome is more similar to that in humans than rodents Tatjana Haitina1, Robert Fredriksson1, Steven M Foord2, Helgi B Schiöth*1 and David E Gloriam*2 Address: 1Department of Neuroscience, Functional Pharmacology, Uppsala University, BMC, Box 593, 751 24, Uppsala, Sweden and 2GlaxoSmithKline Pharmaceuticals, New Frontiers Science Park, 3rd Avenue, Harlow CM19 5AW, UK Email: Tatjana Haitina - [email protected]; Robert Fredriksson - [email protected]; Steven M Foord - [email protected]; Helgi B Schiöth* - [email protected]; David E Gloriam* - [email protected] * Corresponding authors Published: 15 January 2009 Received: 20 August 2008 Accepted: 15 January 2009 BMC Genomics 2009, 10:24 doi:10.1186/1471-2164-10-24 This article is available from: http://www.biomedcentral.com/1471-2164/10/24 © 2009 Haitina et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: The dog is an important model organism and it is considered to be closer to humans than rodents regarding metabolism and responses to drugs. The close relationship between humans and dogs over many centuries has lead to the diversity of the canine species, important genetic discoveries and an appreciation of the effects of old age in another species. The superfamily of G protein-coupled receptors (GPCRs) is one of the largest gene families in most mammals and the most exploited in terms of drug discovery.
    [Show full text]
  • TABLE 1 Studies of Antagonist Activity in Constitutively Active
    TABLE 1 Studies of antagonist activity in constitutively active receptors systems shown to demonstrate inverse agonism for at least one ligand Targets are natural Gs and constitutively active mutants (CAM) of GPCRs. Of 380 antagonists, 85% of the ligands demonstrate inverse agonism. Receptor Neutral Antagonist Inverse Agonist Reference Human β2-adrenergic Dichloroisoproterenol, pindolol, labetolol, timolol, Chidiac et al., 1996; Azzi et alprenolol, propranolol, ICI 118,551, cyanopindolol al., 2001 Turkey erythrocyte β-adrenergic Propranolol, pindolol Gotze et al., 1994 Human β2-adrenergic (CAM) Propranolol Betaxolol, ICI 118,551, sotalol, timolol Samama et al., 1994; Stevens and Milligan, 1998 Human/guinea pig β1-adrenergic Atenolol, propranolol Mewes et al., 1993 Human β1-adrenergic Carvedilol CGP20712A, metoprolol, bisoprolol Engelhardt et al., 2001 Rat α2D-adrenergic Rauwolscine, yohimbine, WB 4101, idazoxan, Tian et al., 1994 phentolamine, Human α2A-adrenergic Napthazoline, Rauwolscine, idazoxan, altipamezole, levomedetomidine, Jansson et al., 1998; Pauwels MPV-2088 (–)RX811059, RX 831003 et al., 2002 Human α2C-adrenergic RX821002, yohimbine Cayla et al., 1999 Human α2D-adrenergic Prazosin McCune et al., 2000 Rat α2-adrenoceptor MK912 RX821002 Murrin et al., 2000 Porcine α2A adrenoceptor (CAM- Idazoxan Rauwolscine, yohimbine, RX821002, MK912, Wade et al., 2001 T373K) phentolamine Human α2A-adrenoceptor (CAM) Dexefaroxan, (+)RX811059, (–)RX811059, RS15385, yohimbine, Pauwels et al., 2000 atipamezole fluparoxan, WB 4101 Hamster α1B-adrenergic
    [Show full text]
  • Profiling G Protein-Coupled Receptors of Fasciola Hepatica Identifies Orphan Rhodopsins Unique to Phylum Platyhelminthes
    bioRxiv preprint doi: https://doi.org/10.1101/207316; this version posted October 23, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Profiling G protein-coupled receptors of Fasciola hepatica 2 identifies orphan rhodopsins unique to phylum 3 Platyhelminthes 4 5 Short title: Profiling G protein-coupled receptors (GPCRs) in Fasciola hepatica 6 7 Paul McVeigh1*, Erin McCammick1, Paul McCusker1, Duncan Wells1, Jane 8 Hodgkinson2, Steve Paterson3, Angela Mousley1, Nikki J. Marks1, Aaron G. Maule1 9 10 11 1Parasitology & Pathogen Biology, The Institute for Global Food Security, School of 12 Biological Sciences, Queen’s University Belfast, Medical Biology Centre, 97 Lisburn 13 Road, Belfast, BT9 7BL, UK 14 15 2 Institute of Infection and Global Health, University of Liverpool, Liverpool, UK 16 17 3 Institute of Integrative Biology, University of Liverpool, Liverpool, UK 18 19 * Corresponding author 20 Email: [email protected] 21 1 bioRxiv preprint doi: https://doi.org/10.1101/207316; this version posted October 23, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 22 Abstract 23 G protein-coupled receptors (GPCRs) are established drug targets. Despite their 24 considerable appeal as targets for next-generation anthelmintics, poor understanding 25 of their diversity and function in parasitic helminths has thwarted progress towards 26 GPCR-targeted anti-parasite drugs.
    [Show full text]
  • Allosteric Modulation of Gabaergic and Glutamatergic Metabotropic Receptors — Thibaud Freyd a Dissertation for the Degree of Philosophiae Doctor – June 2018
    Molecular Pharmacology and Toxicology Faculty of Health Sciences Allosteric modulation of GABAergic and glutamatergic metabotropic receptors — Thibaud Freyd A dissertation for the degree of Philosophiae Doctor – June 2018 Content Acknowledgments ...................................................................................................................... iii List of papers ................................................................................................................................. v Abbreviations ............................................................................................................................. vii Summary .......................................................................................................................................ix 1. Introduction ............................................................................................................................. 1 1.1. Glutamate and GABA neurotransmitters in the CNS ....................................................... 1 1.2. G-protein coupled receptors .................................................................................................... 4 1.2.1. G-protein coupled receptor families ................................................................................................................ 4 1.2.2. Activation of signalling pathways ..................................................................................................................... 5 1.2.3. General structural knowledge ...........................................................................................................................
    [Show full text]
  • Multi-Functionality of Proteins Involved in GPCR and G Protein Signaling: Making Sense of Structure–Function Continuum with In
    Cellular and Molecular Life Sciences (2019) 76:4461–4492 https://doi.org/10.1007/s00018-019-03276-1 Cellular andMolecular Life Sciences REVIEW Multi‑functionality of proteins involved in GPCR and G protein signaling: making sense of structure–function continuum with intrinsic disorder‑based proteoforms Alexander V. Fonin1 · April L. Darling2 · Irina M. Kuznetsova1 · Konstantin K. Turoverov1,3 · Vladimir N. Uversky2,4 Received: 5 August 2019 / Revised: 5 August 2019 / Accepted: 12 August 2019 / Published online: 19 August 2019 © Springer Nature Switzerland AG 2019 Abstract GPCR–G protein signaling system recognizes a multitude of extracellular ligands and triggers a variety of intracellular signal- ing cascades in response. In humans, this system includes more than 800 various GPCRs and a large set of heterotrimeric G proteins. Complexity of this system goes far beyond a multitude of pair-wise ligand–GPCR and GPCR–G protein interactions. In fact, one GPCR can recognize more than one extracellular signal and interact with more than one G protein. Furthermore, one ligand can activate more than one GPCR, and multiple GPCRs can couple to the same G protein. This defnes an intricate multifunctionality of this important signaling system. Here, we show that the multifunctionality of GPCR–G protein system represents an illustrative example of the protein structure–function continuum, where structures of the involved proteins represent a complex mosaic of diferently folded regions (foldons, non-foldons, unfoldons, semi-foldons, and inducible foldons). The functionality of resulting highly dynamic conformational ensembles is fne-tuned by various post-translational modifcations and alternative splicing, and such ensembles can undergo dramatic changes at interaction with their specifc partners.
    [Show full text]
  • International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors
    1521-0081/67/3/601–655$25.00 http://dx.doi.org/10.1124/pr.114.010249 PHARMACOLOGICAL REVIEWS Pharmacol Rev 67:601–655, July 2015 Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics ASSOCIATE EDITOR: ELIOT H. OHLSTEIN International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors Pertti Panula, Paul L. Chazot, Marlon Cowart, Ralf Gutzmer, Rob Leurs, Wai L. S. Liu, Holger Stark, Robin L. Thurmond, and Helmut L. Haas Department of Anatomy, and Neuroscience Center, University of Helsinki, Finland (P.P.); School of Biological and Biomedical Sciences, University of Durham, United Kingdom (P.L.C.); AbbVie, Inc. North Chicago, Illinois (M.C.); Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany (R.G.); Department of Medicinal Chemistry, Amsterdam Institute of Molecules, Medicines and Systems, VU University Amsterdam, The Netherlands (R.L.); Ziarco Pharma Limited, Canterbury, United Kingdom (W.L.S.L.); Institute of Pharmaceutical and Medical Chemistry (H.S.) and Institute of Neurophysiology, Medical Faculty (H.L.H.), Heinrich-Heine-University Duesseldorf, Germany; and Janssen Research & Development, LLC, San Diego, California (R.L.T.) Abstract ....................................................................................602 Downloaded from I. Introduction and Historical Perspective .....................................................602 II. Histamine H1 Receptor . ..................................................................604 A. Receptor Structure
    [Show full text]
  • With [3H]Mepyramine (Trieyclic Antidepressants/Antihistamine/Neurotransmitter/Amitriptyline) VINH TAN TRAN, RAYMOND S
    Proc. Nati. Acad. Sci. USA Vol. 75, No. 12, pp. 6290-6294,, December 1978 Neurobiology Histamine H1 receptors identified in mammalian brain membranes with [3H]mepyramine (trieyclic antidepressants/antihistamine/neurotransmitter/amitriptyline) VINH TAN TRAN, RAYMOND S. L. CHANG, AND SOLOMON H. SNYDER* Departments of Pharmacology and Experimental Therapeutics, and Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 Communicated by Julius Axelrod, August 30,1978 ABSTRACT The antihistamine [3H mepyramine binds to Male Sprague-Dawley rats (150-200 g) were killed by cer- HI histamine receptors in mammalian brain membranes. vical dislocation, their brains were rapidly removed and ho- Potencies of H1 antihistamines at the binding sites correlate mogenized with a Polytron for 30 min (setting 5) in 30 vol of with their pharmacological antihistamine effects in the guinea pig ileum. Specific [3Himepyramine binding is saturable with ice-cold Na/K phosphate buffer (50 mM, pH 7.5), and the a dissociation constant of about 4 nM in both equilibrium and suspension was centrifuged (50,000 X g for 10 min). The pellet kinetic experiments and a density of 10pmolper gram ofwhole was resuspended in the same volume of fresh buffer and cen- brain. Some tricyclic antidepressants are potent inhibitors of trifuged, and the final pellet was resuspended in the original secific [3Hmepamine binding. Regional variations of volume of ice-cold buffer by Polytron homogenization. Calf [3Hjmepyramine ing do not correlate with variations in brains were obtained from a local abattoir within 2 hr after the endogeneous histamine and histidine decarboxylase activity. death of the animals and transferred to the laboratory in ice- Histamine is a neurotransmitter candidate in mammalian brain cold saline.
    [Show full text]
  • Platelets by Burimamide G
    Br. J. Pharmac. (1980), 71, 157-164 INHIBITION OF THROMBOXANE A2 BIOSYNTHESIS IN HUMAN PLATELETS BY BURIMAMIDE G. ALLAN, K.E. EAKINS*, P.S. KULKARNI* & R. LEVI Department of Pharmacology, Cornell University Medical College, New York, N.Y. and *Departments of Opthalmology and Pharmacology, Columbia University College of Physicians & Surgeons, New York, N.Y., U.S.A. 1 Burimamide selectively inhibited the formation of thromboxane A2 from prostaglandin endoper- oxides by human platelet microsomes in a dose-dependent manner (IC50 = 2.5 x 10-5 M). Burima- mide was found to be equipotent to imidazole as a thromboxane synthetase inhibitor. 2 Metiamide, cimetidine and a series of compounds either bearing a structural or pharmacological relationship to histamine caused little or no inhibition of thromboxane A2 biosynthesis by human platelet microsomes. 3 Burimamide (5 x 10-4 to 2.3 x 10- M) did not inhibit either the cyclo-oxygenase or the prosta- cyclin synthetase of sheep seminal vesicles or the prostacyclin synthetase of dog aortic microsomes. 4 Burimamide (2.5 x 10'- to 1.2 x 10-4 M) inhibited sodium arachidonate-induced human platelet aggregation; the degree of inhibition was dependent upon the concentration of arachidonic acid used to aggregate the platelets. Introduction The prostaglandin endoperoxides (prostaglandin G2, (Gryglewski, Zmuda, Korbut, Krecioch & Bieron, H2), the first cyclo-oxygenated products of arachido- 1977). nic acid metabolism can be converted enzymatically Various imidazole derivatives were studied by into either primary prostaglandins such as prosta- Moncada et al. (1977) and of these, only one-methyl glandin E2, F2, or D2, the non-prostanoate throm- imidazole was found to be a potent inhibitor of boxane A2 or prostacyclin (Moncada, Gryglewski, thromboxane A2 biosynthesis.
    [Show full text]
  • The Bitter Taste Receptor Tas2r14 Is Expressed in Ovarian Cancer and Mediates Apoptotic Signalling
    THE BITTER TASTE RECEPTOR TAS2R14 IS EXPRESSED IN OVARIAN CANCER AND MEDIATES APOPTOTIC SIGNALLING by Louis T. P. Martin Submitted in partial fulfilment of the requirements for the degree of Master of Science at Dalhousie University Halifax, Nova Scotia June 2017 © Copyright by Louis T. P. Martin, 2017 DEDICATION PAGE To my grandparents, Christina, Frank, Brenda and Bernie, and my parents, Angela and Tom – for teaching me the value of hard work. ii TABLE OF CONTENTS LIST OF TABLES ............................................................................................................. vi LIST OF FIGURES .......................................................................................................... vii ABSTRACT ....................................................................................................................... ix LIST OF ABBREVIATIONS AND SYMBOLS USED .................................................... x ACKNOWLEDGEMENTS .............................................................................................. xii CHAPTER 1 INTRODUCTION ........................................................................................ 1 1.1 G-PROTEIN COUPLED RECEPTORS ................................................................ 1 1.2 GPCR CLASSES .................................................................................................... 4 1.3 GPCR SIGNALING THROUGH G PROTEINS ................................................... 6 1.4 BITTER TASTE RECEPTORS (TAS2RS) ...........................................................
    [Show full text]
  • The Histamine H3 Receptor: Structure, Pharmacology and Function
    Molecular Pharmacology Fast Forward. Published on August 25, 2016 as DOI: 10.1124/mol.116.104752 This article has not been copyedited and formatted. The final version may differ from this version. MOL #104752 The histamine H3 receptor: structure, pharmacology and function Gustavo Nieto-Alamilla, Ricardo Márquez-Gómez, Ana-Maricela García-Gálvez, Guadalupe-Elide Morales-Figueroa and José-Antonio Arias-Montaño Downloaded from Departamento de Fisiología, Biofísica y Neurociencias, molpharm.aspetjournals.org Centro de Investigación y de Estudios Avanzados (Cinvestav-IPN), Av. IPN 2508, Zacatenco, 07360 México, D.F., México at ASPET Journals on September 29, 2021 Running title: The histamine H3 receptor Correspondence to: Dr. José-Antonio Arias-Montaño Departamento de Fisiología, Biofísica y Neurociencias Cinvestav-IPN Av. IPN 2508, Zacatenco 07360 México, D.F., México. Tel. (+5255) 5747 3964 Fax. (+5255) 5747 3754 Email [email protected] 1 Molecular Pharmacology Fast Forward. Published on August 25, 2016 as DOI: 10.1124/mol.116.104752 This article has not been copyedited and formatted. The final version may differ from this version. MOL #104752 Text pages 66 Number of tables 3 Figures 7 References 256 Words in abstract 168 Downloaded from Words in introduction 141 Words in main text 9494 molpharm.aspetjournals.org at ASPET Journals on September 29, 2021 2 Molecular Pharmacology Fast Forward. Published on August 25, 2016 as DOI: 10.1124/mol.116.104752 This article has not been copyedited and formatted. The final version may differ
    [Show full text]
  • 2 12/ 35 74Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 22 March 2012 (22.03.2012) 2 12/ 35 74 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/16 (2006.01) A61K 9/51 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/14 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/065959 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 14 September 201 1 (14.09.201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/382,653 14 September 2010 (14.09.2010) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, NANOLOGICA AB [SE/SE]; P.O Box 8182, S-104 20 ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, Stockholm (SE).
    [Show full text]
  • Histamine H2-Antagonists, Proton Pump Inhibitors and Other Drugs That Alter Gastric Acidity
    Jack DeRuiter, Principles of Drug Action 2, Fall 2001 HISTAMINE H2-ANTAGONISTS, PROTON PUMP INHIBITORS AND OTHER DRUGS THAT ALTER GASTRIC ACIDITY I. Introduction Peptide ulcer disease (PUD) is a group of upper gastrointestinal tract disorders that result from the erosive action of acid and pepsin. Duodenal ulcer (DU) and gastric ulcer (GU) are the most common forms although PUD may occur in the esophagus or small intestine. Factors that are involved in the pathogenesis and recurrence of PUD include hypersecretion of acid and pepsin and GI infection by Helicobacter pylori, a gram-negative spiral bacterium. H. Pylori has been found in virtually all patients with DU and approximately 75% of patients with GU. Some risk factors associated with recurrence of PUD include cigarette smoking, chronic use of ulcerogenic drugs (e.g. NSAIDs), male gender, age, alcohol consumption, emotional stress and family history. The goals of PUD therapy are to promote healing, relieve pain and prevent ulcer complications and recurrences. Medications used to heal or reduce ulcer recurrence include antacids, antimuscarinic drugs, histamine H2-receptor antagonists, protective mucosal barriers, proton pump inhibitors, prostaglandins and bismuth salt/antibiotic combinations. A characteristic feature of the stomach is its ability to secrete acid as part of its involvement in digesting food for absorption later in the intestine. The presence of acid and proteolytic pepsin enzymes, whose formation from pepsinogen is facilitated by the low gastric pH, is generally assumed to be required for the hydrolysis of proteins and other foods. The acid secretory unit of the gastric + + mucosa is the parietal (oxyntic) cell.
    [Show full text]